Kleangas Energy Technologies Inc (OTCMKTS:KGET), also known as CaliPharms, has been fluctuating in the stock market for over a month, but has started to observe an overall downward trend. The stock is currently trading at a share price of $0.0001, 50% lower than its share value at the start of the month. However, the stock trend is quite surprising given that the company has been making significant progress with its business, in recent weeks. In an update, on February 22, 2017, KGET announced that its CEO, Bo Linton, attended “The Business of Bud: 2017 Cannabis Industry Update”, as a guest.
The Business of Bud event was held at the Golden Gate University, in San Francisco and was completely sold out. The event was held on February 23, 2017 and attracted several business leaders, to speak on the emerging cannabis market and its associated investment, research and regulations. Regarding the event, Mr. Linton stated that this was a great opportunity for the company to educate itself on the latest trends, in the legal cannabis market in California. He claimed that navigating KGET through this highly regulated industry required educating themselves about the industry.
In addition to this, CaliPharms is also reported to be in talks with a medical cannabis edibles company, in California, for possible acquisition. KGET has claimed that its final goal was to become a trusted brand name, in the cannabis space, associated with quality and accurate dosage. As such, the company has stated that it would employ microdosing, in its edible products, in the future. These products include chocolates and mints, among others, where consumers tend to avoid large doses.
On this occasion, Mr. Linton voiced his opinion that the medical cannabis industry would soon become much like the pharmaceutical and health supplements industry. He pointed out that consumers usually want products that actually do what is said on the label, which requires accurate dosage. The CEO also stated that people tend to over-consume edibles, which makes micro-dosing, when dealing with such products, a necessity.
2017 Most Disruptive Biotech VBIOhttp://www.financialstrend.com
Disruptive biotech VBIO decodes targeted drug delivery for stem cells
Top Stock Analysis At Journal Transcripthttp://www.journaltranscript.com
Early bird alerts on the hottest OTC companies
Wall Street PR - BIG BUYOUT OPPORTUNITYhttp://wallstreetpr.com
Here’s how to leverage this breakthrough technology…